JBCHEPHARM Intraday Analysis...

JBCHEPHARM Share Price

Open 283.25 Change Price %
High 283.25 1 Day -5.20 -1.86
Low 265.05 1 Week -14.65 -5.07
Close 274.20 1 Month -10.45 -3.67
Volume 39297 1 Year -94.75 -25.68
52 Week High 403.90
52 Week Low 260.00
JBCHEPHARM Important Levels
Resistance 2 291.07
Resistance 1 284.12
Pivot 274.17
Support 1 264.28
Support 2 257.33
NSE INDIA Most Active Stocks
JPASSOCIAT 17.05 -6.06%
INFIBEAM 119.85 -16.42%
SUZLON 16.10 -1.23%
RCOM 19.90 0.25%
UNITECH 6.65 -4.32%
IBREALEST 201.50 -7.59%
GMRINFRA 16.45 -1.79%
SOUTHBANK 28.60 -2.39%
HFCL 27.95 -4.93%
CAPACITE 342.55 37.02%
More..
NSE INDIA Top Gainers Stocks
CAPACITE 342.55 37.02%
NAGREEKEXP 35.15 19.97%
SHOPERSTOP 500.40 19.68%
LCCINFOTEC 0.35 16.67%
VISASTEEL 19.90 15.70%
TVTODAY 414.45 15.37%
GUFICBIO 83.25 11.90%
SCI 97.95 11.88%
SCI 97.95 11.88%
SCI 97.95 11.88%
More..
NSE INDIA Top Losers Stocks
KSERASERA 0.10 -33.33%
TIFIN 589.55 -25.67%
ADHUNIKIND 63.30 -19.97%
PRAKASHSTL 0.25 -16.67%
INFIBEAM 119.85 -16.42%
VICEROY 19.40 -11.82%
PREMIERPOL 32.35 -11.37%
DAMODARIND 100.25 -10.01%
TINPLATE 224.65 -9.76%
VASWANI 16.90 -9.63%
More..

JB Chemicals & Pharmaceuticals Limited (NSE: JBCHEPHARM)

JBCHEPHARM Technical Analysis 5
As on 25th Sep 2017 JBCHEPHARM Share Price closed @ 274.20 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 331.30 & Strong Sell for SHORT-TERM with Stoploss of 296.98 we also expect STOCK to react on Following IMPORTANT LEVELS.
JBCHEPHARM Target for September
1st Target up-side 300.28
2nd Target up-side 317.72
3rd Target up-side 335.16
1st Target down-side 250.52
2nd Target down-side 233.08
3rd Target down-side 215.64
JBCHEPHARM Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 35.80 Sideways
MFI (14) MFI is 64.81 Sideways
CCI (20) CCI is Below -100 Over Sold
WILLIAM %R (14) William %R is -69.30 Sideways
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Short Sell 294.48
10 Day Avg Volume Traded -63.69 % Less then 10 Day Average Volume
JBCHEPHARM Other Details
Segment EQ
Market Capital 2902640640.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.jbcpl.com
JBCHEPHARM Address
JBCHEPHARM
Neelam Centre
4th floor, B Wing
Mumbai, 400030
India
Phone: 91 22 3045 1200
Fax: 91 22 2493 0534
JBCHEPHARM Latest News
JB Chemicals & Pharmaceuticals Ltd to consider Q3 results on Feb 4, 2015   Equity Bulls   - 01st Jan 15
Buy JB Chemicals Ltd with a target of Rs 265: Ashwani Gujral   Economic Times   - 19th Aug 14
Buy JB Chemicals; target of Rs 251: Sharekhan   Moneycontrol.com   - 07th Aug 14
JB Chemicals & Pharmaceuticals (₹162.1)   Hindu Business Line   - 17th Jul 14
JB Chemicals settles claims with Cilag GmbH, Q1 Net Sales 24% up   Economic Times   - 27th Jul 13
JB Chemicals launches new division   Hindu Business Line   - 30th Jun 11
JB Chemicals eyes in-licensing route for domestic growth   Business Standard   - 28th May 11
JandJ to buy JB Chem's Russian OTC biz   Business Today   - 24th May 11
High pressure on pharma margins; buy JB Chemicals: Sharekhan   Economic Times   - 18th Feb 11
J B Chemicals & Pharmaceuticals Ltd (JBCPL) Long Term Buy Call: StocksIdea ...   TopNews   - 17th Feb 10
Interactive Technical Analysis Chart JB Chemicals & Pharmaceuticals Limited ( JBCHEPHARM NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on JB Chemicals & Pharmaceuticals Limited
JBCHEPHARM Business Profile
JB Chemicals is in the Pharmaceuticals sector. J B Chemicals & Pharmaceuticals (JBC), flagship company of the Unique group, manufactures basic chemicals, petrochemicals, pharmaceuticals, photographic chemicals and agro-based products. Its product portfolio includes metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine). The company has 11 manufacturing facilities across four locations. Its APIs include (metronidazole and its intermediates, diclofenac sodium, potassium and other salts of diclofenac and nifedipine), tablets, injectables (SVP and LVP), liquid suspensions, syrups and ointments markets. It has a fully automated 100 per cent EOU lozenges plant (capacity 400 mn units p.a.) at Daman, manufacturing hard catidies. The company plans to increase therapeutic presence in the high growth chronic care segment. Accordingly, it has launched its CMS division and entered into new therapeutic groups such as anti-diabetics, nutritional and urology segments. It has invested Rs 650 million in a new facility at Panoli, India for manufacture of APIs and large/small volume parenterals. The company`s exports contribute 57 per cent to its revenues. JBC created a new SBU called Zephyr to service emerging needs in the neuro-psychiatric and urology segments. The USFDA has accepted the company`s US DMF for Ciprofloxacin Hydrochloride (API). Once approved, JBC will become the third company in India to have both ANDA and DMF approvals for ciprofloxacin. The company plans to continue its R&D efforts in major thrust areas, namely NDDS, natural products and APIs and to further its therapeutic categories of cardiac care, anti-infective, anti-ulcerants and NSAID. It also has plans for R&D including custom synthesis of specialty intermediates. The current market capitalisation stands at Rs 932.25 crore.The company has reported a standalone sales of Rs 253.19 crore and a Net Profit of Rs 33.14 crore for the quarter ended Sep 2013. The company management includes Durga Dass Chopra - Director, Mahesh K Shroff - Director, Bansidhar S Mehta - Director, Bharat P Mehta - Whole Time Director, Shirish B Mody - Whole Time Director, Dinesh B Mody - Whole Time Director, Rajiv C Mody - Director, Niranjan N Maniar - Director, Jyotindra B Mody - Chairman & Managing Director, Kamlesh L Udani - Executive Director, Pranabh Mody - WholeTime Dire. & President, Jashvantrai B Joshi - Director, Sanjay Asher - Alternate Director, Satyanarain Agarwala - Director, Savya Sachi - Director. It is listed on the BSE with a BSE Code of 506943 and the NSE with an NSE Code of JBCHEPHARM. Its Registered office is at Neelam Centre, B Wing 4th Floor,Hind Cycle Road Mumbai,Maharashtra - 400030.